Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
June 01, 2024 09:00 ET
|
Werewolf Therapeutics, Inc.
- WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy - - Encouraging single agent clinical...
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
May 30, 2024 08:00 ET
|
Werewolf Therapeutics, Inc.
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
May 23, 2024 17:00 ET
|
Werewolf Therapeutics, Inc.
- Updated single agent dose escalation data continues to demonstrate that WTX-124 is well tolerated and clinically active in patients with checkpoint inhibitor therapy relapsed/refractory cancers - ...
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 03, 2024 07:00 ET
|
Werewolf Therapeutics, Inc.
— Company to present an update of its ongoing monotherapy and combination Phase 1/1b trial of WTX-124 in advanced or metastatic solid tumors at ASCO — — Company plans to present interim,...
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024 10:05 ET
|
Werewolf Therapeutics, Inc.
Company to present an update of its ongoing monotherapy and combination Phase 1/1b study of WTX-124 in advanced or metastatic solid tumors WATERTOWN, Mass., April 24, 2024 (GLOBE NEWSWIRE) --...
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
April 23, 2024 08:00 ET
|
Werewolf Therapeutics, Inc.
First Data Demonstrating Application of PREDATOR™ Platform in Immune-Mediated Diseases WATERTOWN, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)...
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
April 05, 2024 16:30 ET
|
Werewolf Therapeutics, Inc.
WTX-518, a conditionally activated IL-18 INDUKINETM molecule that resists suppression by IL-18BP, led to complete tumor regressions in preclinical models WTX-712, a conditionally activated IL-21...
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
April 04, 2024 16:30 ET
|
Werewolf Therapeutics, Inc.
WATERTOWN, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 07, 2024 07:00 ET
|
Werewolf Therapeutics, Inc.
– Additional monotherapy dose-escalation data from ongoing Phase 1/1b clinical trial of WTX-124 expected to be presented in the first half of 2024 – – WTX-124 recommended dose for expansion (RDE),...
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference
March 06, 2024 08:00 ET
|
Werewolf Therapeutics, Inc.
WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...